![Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/09/ced-pexels-13091435.jpg?resize=150%2C150&ssl=1 "Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z] 26")
#80
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
This article matters for clinicians and their patients as it presents findings from a randomized clinical trial on NTI164, a low-THC full-spectrum cannabis extract. The study suggests that this extract significantly reduces seizure frequency in patients with Dravet syndrome, a rare and severe form of epilepsy. This information could potentially expand treatment options for epileptic patients and highlight the therapeutic potential of medicinal cannabis in clinical practice.
In a randomized clinical trial published in Neurotherapeutics, researchers evaluated NTI164, a full-spectrum medicinal cannabis extract with less than 0.3% tetrahydrocannabinol (THC). The study found significant improvements in pain and sleep quality for patients with chronic neuropathic pain, suggesting potential therapeutic benefits for this patient population. Clinicians may consider NTI164 as a low-THC option for managing chronic neuropathic pain symptoms in appropriate cases.
“The recent clinical trial on NTI164 offers promising insights into the potential benefits of low-THC full-spectrum cannabis extracts for certain conditions. However, as a responsible physician, I emphasize that further research and replication in human subjects is crucial to fully understand its therapeutic implications.”
🔬 In the realm of neurotherapy, a recent randomized clinical trial published in Neurotherapeutics has found significant improvements with NTI164, a low-THC full-spectrum cannabis extract. This study suggests potential benefits for patients dealing with treatment-resistant epilepsy. However, it’s crucial to acknowledge the complexity of individual patient responses and the need for further research to confirm these findings and identify any relevant confounders. In clinical practice, this trial underscores the importance of exploring various cannabis extract options as part of a comprehensive treatment plan for refractory epilepsy, always considering each patient’s unique circumstances and potential interactions with other medications.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
📄 Printable 1-Page Physician Patient Guide
Download or print Dr. Benjamin Caplan’s official clinical reference guide to share with your healthcare team.
